Towards a better yardstick: The choice of treatment thresholds in hypertension

Canadian Journal of Cardiology

Volumn 14, Issue 1, 1998, Pages 47-51

  McAlister, Finlay A ^a   Laupacis, Andreas ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Absolute risk; Hypertension guidelines; Patient preferences

Indexed keywords

ANTIHYPERTENSIVE THERAPY; ARTICLE; BORDERLINE HYPERTENSION; CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; RISK; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; COST-BENEFIT ANALYSIS; HUMANS; HYPERTENSION; PRACTICE GUIDELINES; RISK; SEVERITY OF ILLNESS INDEX;

EID: 0031896030     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Jackson R, Barham P, Bills J, et al. Management of raised blood pressure in New Zealand: a discussion document. BMJ 1993:307:107-10.
2. Haynes RB, Lacourciere Y, Rabkin SW, et al. Report of the Canadia Hypertension Society Consensus Conference: 2. Diagnosis of hypertension in adults. Can Med Assoc J 1993:149:409-18.
3. Ogilvie RI, Burgess ED, Cusson JR, Feldman RD, Leiter LA, Myers MO. Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologie treatment of essential hypertension. Can Med Assoc J 1993:149:575-84.
4. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993;153:154-83.
5. Zanchetti A, Chalmers J, Arakawa K, et al. The 1993 guidelines for the management of mild hypertension: memorandum from a WHO/1SH meeting. Blood Press 1993:2:86-100.
6. Sever P, Beevers G, Bulpitt C, et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ 1993:306:983-7.
7. The Sixth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997:157:2413-46.
8. Fahey TP, Peters TJ. What constitutes controlled hypertension? Patient based comparison of hypertension guidelines. BMJ 1996:313:93-6.
9. Ramsay LE, Haq ID, Yeo WW, Jackson PR. Interpretation of prospective trials in hypertension: do treatment guidelines accurately reflect current evidence? J Hypertens 1996;14:S187-94.
10. Alderman MH. Blood pressure management: individualized treatment based on absolute risk and the potential for benefit. Ann Intern Med 1993; 19:329-35.
11. MacMahon S, Peto R, Cutler], et al. Blood pressure, stroke, and coronary heart disease. Part 1: Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-74.
12. MacDonald S, Joffres MR, Stachenko S, Horlick L, Fodor G, for the Canadian Heart Health Surveys Research Group. Multiple cardiovascular disease risk factors in Canadian adults. Can Med Assoc J 1992;146:2021-9.
13. Kaplan NM. Multiple risk factors for coronary heart disease in patients with hypertension. J Hypertens 1995;13:Sl-5.
14. Anderson KM, Wilson PWF, Odell PM, Kännel WB. An updated coronary risk profile: a statement for health professionals. Circulation 1991;83:356-62.
15. Wolf PA, D'Agostino RB, Belanger AJ, Kännel WB. Probability of stroke: a risk profile from the Framingham study. Stroke 1991;22:312-8.
16. Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316 099 white men. Arch Intern Med 1992:152:56-64.
17. Abernethy J, Borhani NO, Hawkins CM, et al. Systolic blood pressure as an independent predictor of mortality in the Hypertension Detection and Follow-up Program. Am J Prev Med 1986;2:123-32.
18. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 1993:153:598-615.
19. Pogue VA, Ellis C, Michel J, Francis CK. New staging system of the Fifth Joint National Committee Report on the Detection, Evaluation, and Treatment of High Blood Pressure (JNC-V) alters assessment of the severity and treatment of hypertension. Hypertension 1996;28:713-8.
20. Davey Smith G, Egger M. Who benefits from medical interventions? Treating low risk patients can be a high risk strategy. BMJ 1994:308:72-4.
21. Hoes AW, Grobbee DE, Lubsen J. Does drug treatment improve survival? Reconciling the trials in mild-to-moderate hypertension. J Hypertens 1995;13:805-11.
22. Levy D. Have expert panel guidelines kept pace with new concepts in hypertension? Lancet 1995:346:1112-3.
23. Krakoff LE. American Society of Hypertension workshop on absolute risk. Am J Hypertens 1996;9:397-9.
24. Jackson RT, Sackett DL. Guidelines for managing raised blood pressure: evidence based or evidence burdened? BMJ 1996;313:64-5.
25. WHO Expert Committee on Hypertension Control. Hypertension control: Report of a WHP Expert Committee [WHO Technical Report Series No 862]. Geneva: World Health Organization, 1996.
26. Black HR, Yi JY. A new classification scheme for hypertension based on relative and absolute risk with implications for treatment and reimbursement. Hypertension 1996;28:719-24-
27. Haq IU, Jackson PR, Yeo WW, Ramsay LE. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet 1995;346:1467-71.
28. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:1728-33.
29. Laupacis A, Sackett DL, Roberts RS. Therapeutic priorities of Canadian internists. Can Med Assoc J 1986;142:329-33.
30. McAlister FA, Laupacis A, Teo KK, Hamilton PG, Montague TJ. A survey of clinician attitudes and management practices in hypertension. J Hum Hypertens 1997:11:413-9.
31. The Clinical Quality Improvement Network (CQIN) Investigators. Cardiovascular risk management among 1806 low risk patients in a primary care setting. CanJ Cardiol 1996;12:797-801.
32. McAlister FA, Teo KK, Lewanczuk RZ, Wells G, Montague TJ. Contemporary practice patterns in the management of newly diagnosed hypertension. Can Med Assoc J 1997:157:23-30.
33. Linjer E, Hansson L. Underestimation of the true benefits of antihypertensive treatment: an assessment of some important sources of error. J Hypertens 1997;15:221-5.
34. Gueyffier F, Boutitie F, Boissel JP, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. Ann Intern Med 1997:126:761-7.
35. Chatellier G, Menard J. The absolute risk as a guide to influence the treatment decision-making process in mild hypertension. J Hypertens 1997:15:217-9.
36. Jaeschke R, Singer ], Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clin Trials 1989:10:407-15.
37. Haq 1U, Ramsay LE, Pickin DM, Yeo WW, Jackson PR, Payne JN. Lipid-lowering for prevention of coronary heart disease: what policy now? Clin Sci 1996;91:399-413.
38. Deber RB, Kraetschmer N, Irvine J. What role do patients wish to play in treatment decision making? Arch Intern Med 1996:156:1414-20.
39. American College of Physicians. Guidelines for counselling postmenopausal women about preventive hormone therapy. Ann Intern Med 1992; 17:1038-41.
40. Hypertension Detection and Follow-Up Program Cooperative Group. The Hypertension Detection and Follow-Up Program. A progress report. CircRes 1977;40(Suppl 1):1106-14.
41. Reader R, Bauer GE, Doyle AE, et al. The Australian Therapeutic Trial in Mild Hypertension. Lancet 1980;i:1261-7.
42. Johannesson M. The cost-effectiveness of hypertension treatment in Sweden. Pharmacoeconomics 1995;7:242-50.